M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
124 deals · US$156bndisclosed · Biotech · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Feb 2026 | Orna Therapeutics | – | Eli Lilly and Company | Acquisition | Announced | 2,400.0 | Biotech+1 | Lazard (sell-side)Goodwin (sell-side)Paul, Weiss (buy-side) |
| Feb 2026 | PrimeGen US | – | DT Cloud Star Acquisition | Merger | Announced | 1,500.0 | Biotech+1 | A.G.P./Alliance Global Partners (sell-side)Sichenzia Ross Ference Carmel (sell-side)Loeb & Loeb (buy-side) |
| Jan 2026 | Repare Therapeutics | – | XenoTherapeutics | Acquisition | Completed | – | Biotech+1 | Cooley (sell-side)Stikeman Elliott (sell-side) |
| Jan 2026 | AbelZeta's 50% share of China development and commercialisation rights to C-CAR031 | AbelZeta | AstraZeneca | Asset sale | Announced | 630.0 | Biotech+2 | Davis Polk (sell-side) |
| Jan 2026 | RAPT Therapeutics | – | GSK | Acquisition | Announced | 2,200.0 | Biotech+1 | J.P. Morgan (sell-side)Cooley (sell-side)Latham & Watkins (sell-side)Evercore (buy-side)A&O Shearman (buy-side) |
| Jan 2026 | SL Bio | – | Horizon Space Acquisition II Corp. | Merger | Announced | 5,568.0 | Biotech | VCL Law (sell-side)Ogier (sell-side)King Kee Appraisal and Advisory (buy-side)Robinson & Cole (buy-side)Maples Group (buy-side) |
| Jan 2026 | InduPro Therapeutics | – | Eli Lilly and Company | Stake | Announced | – | Biotech+2 | Freshfields (buy-side) |
| Jan 2026 | Ventyx Biosciences | – | Eli Lilly and Company | Acquisition | Announced | 1,200.0 | Biotech+2 | Jefferies (sell-side)Moelis & Company (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Ropes & Gray (buy-side) |
| Jan 2026 | Dark Blue Therapeutics | – | Amgen | Acquisition | Completed | 840.0 | Biotech+2 | Goodwin (sell-side)BofA Securities (sell-side) |
| Jan 2026 | Mersana Therapeutics | – | Day One Biopharmaceuticals | Acquisition | Completed | – | Biotech+2 | TD Securities (sell-side)WilmerHale (sell-side)Gordon Dyal & Co. (buy-side)Fenwick & West (buy-side) |
| 2026 | Calytrix Bio | – | Eli Lilly | Acquisition | Announced | 1,500.0 | Biotech | Centerview Partners (sell-side) |
| 2026 | AttaiBeckley | – | Eli Lilly and Company | Acquisition | Announced | 3,800.0 | Biotech+2 | Moelis & Company (sell-side) |
| 2026 | FireFly Biologics | – | J&J | Acquisition | Announced | 1,000.0 | Biotech+1 | Centerview Partners (sell-side) |
| Dec 2025 | Dynavax Technologies | – | Sanofi | Acquisition | Announced | 2,200.0 | Biotech+1 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Cooley (sell-side)Weil, Gotshal & Manges (buy-side) |
| Dec 2025 | Amicus Therapeutics | – | BioMarin | Acquisition | Announced | 4,800.0 | Biotech+2 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Kirkland & Ellis (sell-side)Morgan Stanley (buy-side)Jones Day (buy-side) |
| Dec 2025 | Generation Bio Co. | – | XRA 7 Corp. | Acquisition | Announced | – | Biotech+1 | TD Securities (sell-side)WilmerHale (sell-side)Gibson Dunn (buy-side) |
| Dec 2025 | MindWave Innovations | – | Apimeds Pharmaceuticals US | Merger | Completed | – | Biotech+1 | Duane Morris (sell-side)Nelson Mullins Riley & Scarborough (buy-side) |
| Nov 2025 | Aptose Biosciences | – | HS North America | Acquisition | Announced | – | Biotech+2 | Locust Walk (sell-side)Stikeman Elliott (buy-side) |
| Oct 2025 | Avidity Biosciences | – | Novartis | Acquisition | Announced | 11,000.0 | Biotech+2 | Goldman Sachs (sell-side)Barclays (sell-side)Kirkland & Ellis (sell-side)Covington & Burling (buy-side)Freshfields (buy-side)Gordon Dyal & Co. (buy-side) |
| Oct 2025 | Astria Therapeutics | – | BioCryst Pharmaceuticals | Acquisition | Completed | 700.0 | Biotech+2 | Evercore (sell-side)Sidley Austin (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side) |
| Jul 2025 | DiamiR Biosciences Corp. | – | Aptorum Group | Merger | Completed | – | Diagnostics+1 | H.C. Wainwright & Co. (sell-side) |
| Feb 2025 | Instinct Bio Technical Company | – | Relativity Acquisition Sponsor | Merger | Pending | 225.0 | Biotech | Hunter Taubman Fischer & Li (sell-side)Chardan (sell-side)Loeb & Loeb (buy-side)Ogier (buy-side) |
| – | Barinthus Biotherapeutics | – | – | Merger | Announced | – | Biotech | Oppenheimer & Co. (sell-side)Snell & Wilmer (sell-side)D. Boral Capital (buy-side) |
| – | Telomir Pharmaceuticals | – | – | Merger | Announced | 47.1 | Biotech+1 |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.